首页> 外文期刊>Trials >The effectiveness and cost-effectiveness of 3- vs. 6-monthly dispensing of antiretroviral treatment (ART) for stable HIV patients in community ART-refill groups in Zimbabwe: study protocol for a pragmatic, cluster-randomized trial
【24h】

The effectiveness and cost-effectiveness of 3- vs. 6-monthly dispensing of antiretroviral treatment (ART) for stable HIV patients in community ART-refill groups in Zimbabwe: study protocol for a pragmatic, cluster-randomized trial

机译:津巴布韦社区ART补充药组中稳定HIV病人接受抗逆转录病毒治疗(ART)的3个月/ 6个月的有效性和成本效益:一项实用的,集群随机试验的研究方案

获取原文
           

摘要

Sub-Saharan Africa is the world region with the greatest number of people eligible to receive antiretroviral treatment (ART). Less frequent dispensing of ART and community-based ART-delivery models are potential strategies to reduce the load on overburdened healthcare facilities and reduce the barriers for patients to access treatment. However, no large-scale trials have been conducted investigating patient outcomes or evaluating the cost-effectiveness of extended ART-dispensing intervals within community ART-delivery models. This trial will assess the clinical effectiveness, cost-effectiveness and acceptability of providing ART refills on a 3 vs. a 6-monthly basis within community ART-refill groups (CARGs) for stable patients in Zimbabwe. In this pragmatic, three-arm, parallel, unblinded, cluster-randomized non-inferiority trial, 30 clusters (healthcare facilities and associated CARGs) are allocated using stratified randomization in a 1:1:1 ratio to either (1) ART refills supplied 3-monthly from the health facility (control arm), (2) ART refills supplied 3-monthly within CARGs, or (3) ART refills supplied 6-monthly within CARGs. A CARG consists of 6–12 stable patients who meet in the community to receive ART refills and who provide support to one another. Stable adult ART patients with a baseline viral load?
机译:撒哈拉以南非洲是世界上拥有接受抗逆转录病毒治疗(ART)的人数最多的地区。减少ART分配频率和基于社区的ART传递模型是减轻负担过重的医疗机构负担并减少患者获得治疗的障碍的潜在策略。但是,尚未进行大规模的临床试验来研究患者的预后或评估社区ART传递模型中延长ART分配间隔的成本效益。这项试验将评估津巴布韦稳定患者在社区ART补充药组(CARG)中每3个月和6个月一次提供ART补充药的临床有效性,成本效益和可接受性。在该实用的,三臂,平行,无盲,成簇随机的非劣效性试验中,使用分层随机分配比例为1:1的30个集群(医疗机构和相关的CAG)分配给(1)个ART笔芯每月从医疗机构(控制机构)获得3个月的服务;(2)在CARG中每月提供3个月的ART笔芯,或(3)在CARG中每月提供6个月的ART笔芯。 CARG由6-12位稳定的患者组成,他们在社区见面接受ART补充治疗,并相互提供支持。基线病毒载量≤1000拷贝/ ml的稳定成人ART患者将被邀请参加(每组1920名参与者)。主要结果是入选后12个月仍活着并保留在护理中的参与者比例。次要结果(在12和24个月时测量)是达到病毒抑制的比例,每个参与者的平均提供者成本,保留的每个参与者的提供者成本,被病毒抑制的保留的每个参与者的成本以及获得治疗的平均患者水平的成本。定性研究将评估CARG中延长的ART分配间隔对提供者和患者的可接受性,并且将评估由于干预而导致的潜在设施级拥堵的指标。为了适应撒哈拉以南非洲地区大量稳定的ART患者,迫切需要能够维持高水平患者保留的具有成本效益的卫生系统模型。这将是第一个评估以社区为基础的ART分配模型中延长ART分配间隔的试验,其结果旨在为国家和地区政策提供有关其对卫生保健系统和患者的潜在益处的信息。 ClinicalTrials.gov,ID:NCT03238846。 2017年7月27日注册。

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号